Bayer Cash Flow from Operating Activities 2010-2024 | BAYRY

Bayer annual/quarterly cash flow from operating activities history and growth rate from 2010 to 2024. Cash flow from operating activities can be defined as a company's cash flows from operations.
  • Bayer cash flow from operating activities for the quarter ending December 31, 2024 was $7.973B, a 43.96% increase year-over-year.
  • Bayer cash flow from operating activities for the twelve months ending December 31, 2024 was $8.526B, a 496.75% decline year-over-year.
  • Bayer annual cash flow from operating activities for 2024 was $7.973B, a 43.96% increase from 2023.
  • Bayer annual cash flow from operating activities for 2023 was $5.538B, a 25.89% decline from 2022.
  • Bayer annual cash flow from operating activities for 2022 was $7.473B, a 24.12% increase from 2021.
Bayer Annual Cash Flow Ops
(Millions of US $)
2024 $7,973
2023 $5,538
2022 $7,473
2021 $6,021
2020 $5,601
2019 $9,192
2018 $9,350
2017 $9,194
2016 $10,058
2015 $7,651
2014 $7,723
2013 $6,869
2012 $5,829
2011 $7,048
2010 $7,666
2009 $7,496
Sector Industry Market Cap Revenue
Medical Large Cap Pharma $25.425B $50.438B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) US $752.942B 57.71
Johnson & Johnson (JNJ) US $371.642B 15.37
AbbVie (ABBV) US $342.014B 18.83
Novo Nordisk (NVO) DK $294.382B 19.94
Roche Holding AG (RHHBY) CH $252.439B 0.00
Novartis AG (NVS) CH $235.176B 13.43
Merck (MRK) US $209.962B 10.69
Sanofi (SNY) FR $136.671B 13.07
Pfizer (PFE) US $135.718B 7.45
Innoviva (INVA) US $1.169B 10.78